The authors certify that all research involving human subjects was done under full compliance with all government policies and the Helsinki Declaration.
effects on neurons through neurotrophic factors including nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor during responses against infection, injury, cellular debris, or abnormal protein aggregates (Belanger and Magistretti, 2009; Hansebout et al., 2012) . In addition to neuroprotection mediated by secreted factors, astrocytes significantly contribute to the exclusion and metabolism of toxins as part of the blood-brain barrier (BBB) (Meyer et al., 2001) . The BBB protects the brain from fluctuations in plasma composition and from circulating agents such as neurotransmitters and xenobiotics capable of disturbing neuronal function (Abbott et al., 2006) . Astrocytic tripeptide glutathione (GSH) can serve as an electron donor in GSH peroxidase-catalyzed reduction of peroxides as well as act as a substrate in the detoxification of xenobiotics (Dringen et al., 2015; Meyer et al., 2001) . Less is known about the role of astrocytes in metabolizing toxicants through other pathways. P450 in the liver has an important role in the metabolism and detoxification of xenobiotics for subsequent elimination (Forrester et al., 1992) and astrocytes express multiple forms of P450 (Kempermann et al., 1994; Malaplate-Armand et al., 2004) . Therefore, astrocytes in a developing central nervous system (CNS) may function as a second line of defense, primarily through the BBB and second by metabolizing toxins. Thus, to assess the effect of a neurotoxic agent, it is vital to understand the innate ability of neurotoxins to cross the BBB, as well as how astrocytes metabolize toxicants that can cross the BBB.
Chlorpyrifos (CPF) is one of the most widely used insecticides in both developing and industrialized countries, including the United States (Yang et al., 2011) . Acute CPF exposure can lead to neurotoxicity in humans by inhibiting acetylcholinesterase-mediated breakdown of the neurotransmitter acetylcholine (Costa et al., 2008) . CPF can also form adducts with other proteins, impairing various molecular pathways in humans (Yang and Bartlett, 2016) . The negative effects of CPF is evident over a wide neural developmental period, including early development stages affecting neural cell proliferation and differentiation, and axonogenesis (Qiao et al., 2001 (Qiao et al., , 2004 . CPF may cross the BBB and disrupt BBB integrity and function by altering gene expression for claudin5, TRPC4 and ZO1 (Li and Ehrich, 2013) . CPF alteration in BBB function is reversible upon removal of CPF (Li and Ehrich, 2013; Parran et al., 2005) . Metabolism of CFP by P450 in animals alters neurotoxicity. CPF-oxon (CPO) does not diminish and may enhance neurotoxicity whereas the 3, 5, 6-trichloropyridinol (TCP) metabolite is much less toxic to axonal and growth (Howard et al., 2005) .
Informative primary CNS cell cultures and animal studies investigated the effects of CPF and metabolites but do not address cell type specific effects, such as astrocytes. Highly enriched human astrocyte populations of human astrocytes in combination with neurons phenotypes have not been studied. In coculture studies using primary rat hippocampal astrocytes with either primary rat hippocampal neurons or rat PC12 cells, astrocytes have been shown to protect neurons against toxicity of oxidative stress (Anderl et al., 2009) . Recent studies suggest that astrocytes in an in vitro neurotoxicity test system may prove more relevant to human CNS structure and function than neuronal cells alone (Wu et al., 2014) . Human pluripotent stem cell (hPSC)-derived astrocytes have an integral role in the maintenance of early neuronal differentiation and neurite outgrowth (Gupta et al., 2012) . Human neural progenitor (hNP) cells differentiated from hPSC offer a potentially unlimited and uniform cell source for developmental neural toxicity (DNT) assays (Radio and Mundy, 2008) . hNP-derived astrocytes and neurons provide an ideal platform to mimic heterotypic cellular interaction in the CNS in an in vitro coculture model.
Although high levels of P450 were reported in astroglial cells (Kempermann et al., 1994; Malaplate-Armand et al., 2004) , astrocyte neuroprotective qualities are understudied and humanspecific implications are unknown. We sought to more fully understand CPF effects in hPSC-derived neurons, astrocytes and astrocyte-neuron coculture systems to directly address a potential astrocyte role and mechanism in DNT protection. In this study, we show that CPF inhibited neurite outgrowth in a dosedependent manner during 48 h exposure. However, the neurotoxic effect of CPF was rescued by the addition of astrocytes, which likely metabolized CPF. Further, a noncytotoxic low dose of a P450 inhibitor partially reversed this protective effect. Thus, for the first time, we have established a high content hPSCderived astrocyte-neuron coculture system and identified a role for the astrocytic P450 enzyme activity in neuroprotection upon exposure to the known neurotoxicant CPF.
MATERIALS AND METHODS

Cell Maintenance
Cryopreserved hNPs, NeuroNet pure human neurons (DIV 28 neurons) and hAstroPro human astrocyte cells (ArunA Biomedical Inc., Athens, Georgia) were thawed and maintained according to manufacturer's instructions. Postthaw, live cells were counted by a trypan blue cell viability test. Cells were cultured in AB2 basal medium supplemented with ANS neural supplement (both from ArunA Biomedical Inc.), 2 mM L-glutamine (Gibco, Gaithersburg, Maryland), 50 U/ml penicillinstreptomycin (Gibco) and 10 ng/ml leukemia inhibitory factor (Millipore, Billerica, Massachusetts) on costar 96-well cell culture plate (Corning Incorporated, Corning, New York) precoated for one hour with growth factor reduced-Matrigel basement membrane matrix (R&D, Minneapolis, Minnesota) (diluted in AB2 basal medium 1:100). In the neuron-only group, DIV 28 neurons were plated at 10 000 live cells/well, while in the coculture group, DIV 28 neurons and hAstroPro were cultured at 10 000 live cells/well each.
Chemical Treatment CPF (99.5% pure), CPO (98.5% pure), and TCP (99% pure) were all purchased from Chem Service (West Chester, Pennsylvania) and the P450 inhibitor proadifen hydrochloride (SKF-525A) from Abcam (Cambridge, Massachusetts). Test compounds were prepared as 0.15, 0.5, 1.5, 5, 15 mM stock solutions in DMSO and were then diluted to 50Â in AB2/ANS, with another 10Â dilution in culture to make final concentration of 0.3, 1, 3, 10, and 30 lM. SKF-525A was prepared in distilled water as stock solution: 2.5, 5, 10, 20, 40 mM with 1000Â dilution in medium to make final concentrations: 2.5, 5, 10, 20, and 40 mM. Compounds were added to cell cultures 2 h after cells were seeded in 96-well culture plates and incubated for 48 h before immunocytochemical analysis.
Immunocytochemistry
Immunofluorescent staining was performed using the Eppendorf epMotion liquid handling system for automated fixing and staining. Cells were stained as described previously with minor modifications to the protocol (Gallegos-Cardenas et al., 2015) . Briefly, cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, Pennsylvania). 100 ll of a warm (37 C) solution of 8% paraformaldehyde were added to culture wells containing 100 ll of medium and incubated at room temperature for 20 min (Doherty et al., 2000) . Image Acquisition and Analysis A Cellomics ArrayScan VTI high-content imaging system (ThermoFisher Scientific, Waltham, Massachusetts) was used for automated image acquisition and morphometric analyses as previously described for use on hN2 cells (Harrill et al., 2010) . Cell body validation was quantified based on MAP2 positive expression in DIV 28 neurons. In this study, 35 fields at 20Â magnification were sampled per well for cell characterization. Image analysis algorithm optimization, including nucleus validation, cell body masking and validation, and neurite tracing parameters, was performed a priori using 5 representative images from cultures with untreated DIV 28 neurons and cocultured cells. Output from high content image analysis included total cell count (cell density, % MAP2 cells per well) and measurements of neurite outgrowth (neurites per neuron, neurite length per neuron, and branch points per neuron). Briefly, nuclei were first identified by Hoechst staining (channel 1) as bright objects on a dark background (Figs. 2A and 3A) . Nuclei with size and intensity values outside of the ranges determined a priori for viable cells were identified in the channel 1 image and rejected from further analyses. To determine live cells and exclude dead cells, Cellomics Neural Profiling Bioapplication was used to distinguish live cell nuclear based on average intensity and area from dead cells. The bioapplication calculated live cell nucleus Hoechst staining average intensity and area. To be considered a live cell, the nucleus had a Hoechst staining intensity below 1000 and nuclear area above 65. A cell with a nucleus with intensity score above 1000 or nuclear area below 65 was considered a dead cell and excluded for analysis as reported in Figs. 4A-C). Spatial coordinates from the channel 1 image were then superimposed on the matching MAP2 image (channel 2) to distinguish bona fide MAP2þ neurons from background noise. MAP2 cells were defined based on user-defined geometric and signal intensity-based parameters (Figs. 2B and 3B). Astrocytes were rejected through an increased threshold set based on fluorescent intensity. Positive MAP2 neurons were selected based on average fluorescent signal intensity level value (450) determined using neuron-only cultures and astrocytes were rejected based on fluorescent signal intensity threshold lower than 450 (Figs. 2B and 3B). Data were collected on a cell-by-cell basis, and values were averaged to obtain population means within each well. These well level data were treated as replicate statistical unit for analysis of neurite outgrowth.
Data Acquisition and Analysis of Metabolites
Sample preparation. Each 100 ll of cell culture media was extracted with 1.7 ml isopropyl ether. The mixture was vortexed for 10 min, then centrifuged at 7500 Â g, 5 C for 10 min. 1.5 ml supernatant was transferred and evaporated at 55 C for 10 min to complete dryness in the vacuum concentrator. The sample was reconstituted with 100 ll acetonitrile (ACN), sonicated, vortexed, and centrifuged at 7500 Â g, 5 C for 10 min 80 ll supernatant was transferred into the autosampler vial for injection.
Instrumentation. An Agilent 1100 binary pump HPLC system (Santa Clara, California) coupled with a Waters Micromass Quattro Micro triple quadrupole mass spectrometer with an ESI source (Milford, Massachusetts) was operated for LC-MS/MS analysis. Masslynx 4.0 software by Waters (Beverly, Massachusetts) was used for data processing. A Labconco CentriVap Complete Vacuum Concentrator (Kansas City, Missouri) was utilized to evaporate samples.
LC-MS/MS conditions.
A Zorbax Eclipse XDB-C8 (2.1 Â 150 mm, 5 lm) column coupled with a Phenomenex SecurityGuard C-8 guard column (4.0 Â 2.0 mm) was used to separate the analytes. The column temperature was controlled at 32 C. The mobile phase A was 0.025% formic acid in water, mobile phase B was ACN. The injection volume was 15 ll. Analytes were separated using a gradient method, with a 0.3 ml/min flow rate, (time/ minute, % mobile phase B): (0, 60), (2, 80), (2.01, 80), (5, 80), (6, 60), (10, 60). The LC system was interfaced by a 6-port divert valve to the mass spectrometer, introducing eluents to the ion source. The autosampler injection needle was washed with methanol after each injection. Samples were analyzed by the mass spectrometer in negative ion mode for TCP. Nitrogen was used as the desolvation gas at a flow rate of 500 L/h. The desolvation temperature was 500 C and the source temperature was 120 C.
Argon was used as the collision gas and the collision cell pressure was 3.5 Â 10-3 mbar. The capillary voltage was 4 kV andthe cone voltage was À22 V for TCP. A selected ion recording of 198 was applied for the quantitation of TCP. Diisopropyl ether, LC-MS grade ACN, methanol, water, and formic acid were purchased from Sigma-Aldrich. TCP was detected at a retention time of 2.35 min using a TCP standard. Figure 5 were analyzed using 1-way ANOVA with a significance threshold of P < .05 followed by a Tukey's test. Neuronal total cell count and neurite outgrowth in coculture was analyzed using 2-way ANOVA with a significance threshold of P < .05 ( Figure 5 and Supplementary Figure 3) . Mean values 6 SD for all measurements are provided throughout the text. Statistical analyses were performed using Graphpad Prism 5.
Statistics
Concentration-response experiments in Figures 2 and 4 as well as P450 inhibition experiment in
RESULTS
MAP2 Expression Marks Neurites in a Pure Neuronal Population Derived From hNP Cells
The NeuroNet cells derived from hNP cells and cryopreserved after 28 days of differentiation (DIV 28) exhibit typical neuronal morphology within 48 h postthaw, and cultures include robust neurite outgrowth ( Figure 1A ). To characterize these cultures in terms of neuronal maturity, we colabeled the cells with the neuron-specific markers bIII-tubulin and MAP2 (Figs. 1C and D, respectively) . Both bIII-tubulin and MAP2 were present in 96.5% of viable cells and were localized in cell bodies and neurites ( Figure 1E ). hNP cell cultures were negative for MAP2 expression ( Figure 1F ).
CPF Reduces Cell Density and Inhibits Neurite Outgrowth
To compare the inhibitory effect of CPF with its metabolites CPO and TCP on DIV 28 neurons, cells were incubated with a serial concentration of all 3 chemicals. Following continuous exposure for 48 h, cells were immunostained with MAP2 and quantified in a high content imaging system ( Figs. 2A-C) . CPF reduced cell density only at the highest concentration tested, 30 mM, by 23% ( Figure 2D ) while CPO and TCP had no effect at any of the concentrations tested ( Figure 2D ). CPF inhibited neurites per neuron, neurite length per neuron, and branchpoints per neuron at 10 mM (9%, 12%, 19% reductions, respectively) without reducing cell density (Figs. 2E-G) . CPO, while not affecting cell density at any concentration, inhibited neurite length per neuron by 14% at 10 mM, and neurites per neuron, neurite length per neuron, and branchpoints per neuron at 30 mM by 15%, 25%, 22% (Figs. 2E-G). TCP incubation did not reduce cell density or inhibit any of the neurite outgrowth parameters (Figs. 2D-G) at the same concentrations.
Astrocytes Reduce Toxic Effect of CPF on Neurons
To investigate possible modulation of CPF neurotoxicity on DIV 28 neurons in the presence of astrocytes, 2 groups, neuron-only and astrocyte-neuron cocultures, were incubated with CPF. Cell numbers and neurite outgrowth parameters were then quantified in high content imaging system using MAP2-positive cells (Figs. 3A-C ). Both total cell density and neurite outgrowth were compared between neuron-only and astrocyte-neuron cocultures groups. The presence of astrocytes did not significantly alter CPF-induced toxicity on cell density ( Figure 3D ). However, astrocytes rescued neurite number, neurite outgrowth and branchpoint phenotypes (Figs. 3E-G, respectively). Neurites per neuron were increased in cocultures by 10% at 10 mM and 24% at 30 mM ( Figure 3E ). Neurite length per neuron was increased in the cocultured group by 13% at 10 mM and 31% at 30 mM ( Figure 3F ). Branchpoints per neuron were increased in cocultured group by 14.99% at 10 mM and 27.34% at 30 mM ( Figure  3G ). Both a positive and a negative contemporary control compounds were used. Bisindolylmaleimide I (Bis-I) was the positive control for this study (Supplementary Figure 2) . Bis-I interferes with cytoskeleton function in neurons and was used as a positive control in our studies since we and others have previously published on the effects of this compound in DNT human neurite assays (Harrill et al., 2010; Wu et al., 2016) . In both neurononly and in cocultures Bis-I at noncytotoxic doses affected neurite outgrowth parameters. The branchpoint per neuron was significantly different in neuron-only versus coculture group and neurites per neuron, neurite length per neuron, and branchpoint per neuron per field was different between neuron-only and coculture groups (Supplementary Figure 2) . In addition, amoxicillin, has low neurotoxicity and none was observed at the doses used and served as the negative control (Supplementary Figure 1) .
P450 Inhibitor Reduces Effects of Astrocyte on CPF Neurotoxicity in Cocultures
We next interrogated the potential role of P450 as a mediator of astrocytic neuroprotection using the P450 inhibitor SKF525A. To determine a safe dose, a series of concentrations of the SKF525A were added in the absence of CPF to the astrocyte-only, neurononly and cocultured groups. In the cocultured group, cell density was inhibited by 20 and 40 mM SKF525A but not at lower concentrations ( Figure 4A ). Cell density was reduced by 29% in the astrocyte-only group at 20 mM SKF525A ( Figure 4B ). In the neuron-only group, cell density was decreased at 20 and 40 mM by 35% and 48% ( Figure 4C ). Based on these cytotoxicity results (Figs. 4A-C), 10 mM SKF525A was chosen for further studying the role of P450 in CPF metabolism since this dose was not toxic to both astrocytes and DIV 28 neurons. In the cocultured group, CPF did not inhibit neurite length and number of neurites per neuron in presence of SKF525A. However, branchpoints per neuron decreased in a dose-dependent manner in presence of SKF525A (67%-71% in 5 and 10 mM, respectively, Figure 4D ). Taken together, our data indicate that astrocyte P450 activity has a role in reversing at least some DNT effects of CPF.
CPF Metabolism to TCP in Astrocyte Is Reduced by P450 Inhibitor
To test whether astrocytic P450 might impart neuroprotection by metabolizing neurotoxic CPF to the nontoxic TCP, similar to the role of P450 in the liver (Lee et al., 2009), we quantified TCP by LCMS in media from neuron-only, astrocyte-only, and cocultured cell populations in the presence and absence of SKF525A (Figs. 5A-F). TCP levels in astrocytes and neurons cultured in the absence of CPF were first quantified to validate the system. Both astrocytes and neurons cell lysis have no TCP detected as shown in Supplementary Figure 3 . In the neuron-only group, levels of TCP detected in media were not different in the presence and absence of SKF525A. However, TCP levels in astrocyteonly and coculture media were significantly higher in the absence of SKF525A as shown by preliminary peak area quantification (Figs. 5A-F) . In the astrocyte group, TCP concentrations in media detected by LCMS quantification were 1011 ng/ml after 48 h incubation with CPF. In the astrocyte-only group with both CPF and SKF525A treatment, the TCP concentration was 67 ng/ml. In cocultures, TCP concentration was 1347 ng/ml after 48 h incubation with CPF without SKF525A. In the coculture group with both CPF and SKF525A treatment, TCP concentration decreased to 54 ng/ml. In neuron-only cultures, SKF525A caused no significant difference in TCP concentrations (61 ng/ml in the absence of SKF525A, 51 ng/ml in the presence of SKF525A ( Figure 5G ). TCP concentration (1347 ng/ml) in the coculture group was significantly higher than in the astrocyte group (1011 ng/ml) in absence of SKF525A ( Figure 5G) . A schematic summarizes our observations and conclusions on the mechanism of action of CPF neurotoxicity on neurite outgrowth including cell density, neurite number, neurite length, and branch points per neuron ( Figure 6A ). In the presence of astrocytes, CPF neurotoxicity was significantly reduced on all neurite outgrowth measurement through metabolism of CPF to TCP by P450 ( Figure 6B ). When P450 activity in astrocyte was inhibited by SKF525A, CPF metabolism to TCP was blocked in astrocytes reducing their ability to protect neurons from CPFinduced neurotoxicity ( Figure 6C ).
DISCUSSION
Greater than 70 000 chemicals in commerce need regulatory testing, thus, less expensive high-throughput in vitro systems are needed to prioritize chemicals (Schaefer, 1994) . Use of a controlled coculture of human neurons and astrocytes could provide the CNS tissue representation needed to uniformly and reproducibly predict neurotoxicities for large sets of compounds. We used highly enriched neurons and astrocytes which should reduce variability within and between screening campaigns. It also allows for defined ratios of astrocytes to neurons in cocultures, which provides a more accurate and physiological representative in vitro model mimicking in vivo neural tissue where regional differences in astrocytes to neurons ratios are documented (Herculano-Houzel, 2014; Woehrling et al., 2007) . Reported glia to neuron ratios varies, from 1:1 to 10:1 glianeuron ratio, and the proportion of glial to neuronal cells depended on the human CNS regions that was examined (Herculano-Houzel 2014; Hilgetag and Barbas, 2009) . Thus, it is advantageous to have a flexible system, like that reported here, where ratios could be altered to represent differing studies. Our hPSC-derived neuron-astrocyte coculture DNT system provided further insights into how astrocytes provide neuroprotective effects. Interestingly, we showed that CPF metabolism to nontoxic TCP was more efficient in astrocytes in coculture than in the astrocyte-only cultures, potentially indicating an interactive role between astrocytes and neurons in CPF metabolism. This type of information can only be observed in systems where cell types are both screened in isolation and in combination with other CNS cell types.
Although the concept of an in vitro cell-based DNT system is not new, the majority of reported systems either depend on primary cells sourced from animals, limiting scalability, throughput, uniformity and species representation, or on transformed cells. In contrast, nontransformed potentially unlimited lineage-restricted cell source that is easily scalable for highthroughput DNT screening has advantages (Fukushima et al., 2016) . Here, hNP cells differentiated for 28 days (NeuroNet) were highly enriched for cells expressing the mature neuronal marker MAP2 and Tuj-1, demonstrating purity and maturity of the neurons. Combined with a pure human astrocyte population, we achieve a controlled coculture, unlike cocultures established with primary cells that may contain contaminating cell types as well as varying astrocyte to neuron ratios among primary preparations (Kidambi et al., 2008) .
In regions of agriculture where CPF was used, 70% of pregnant mothers had detectable levels of CFP in their circulation. Blood levels of CPF ranged from nondetectable to 3.95 mM in pregnant women and from nondetectable to about 4.92 mM in newborns (Huen et al., 2012) . In patients with acute CPF poisoning, blood CPF concentration can reach 12 mM (Eyer et al., 2009) . These concentrations are in the range of CPF dosage in this study suggesting these were representative doses of potential CPF exposure in the CNS. Although CPF metabolism studies focus on liver microsomes and hepatocytes due to abundance of P450, it does not rule out other route of CPF exposure such as inhalation. CPF crosses the BBB (Parran et al., 2005) and like other small molecules, it is plausible that a portion of inhaled CPF may also bypass circulation and pass directly into the CNS via the olfactory bulb. Also, a lack of circulating CPO in serum suggests that metabolic activation within the CNS may be responsible for CPF neurotoxicity (Khokhar and Tyndale, 2012) . Recently the important contributing role of astrocytes P450-mediated metabolism in drug or neurotoxin metabolism helped decipher toxicity when plasma levels did not predict drug or toxin response (Miksys and Tyndale, 2003) . Therefore, neural niche specific CPF metabolism may have a major biological effect on the local neuron population.
In previous hPSC studies, CPF inhibited neurite outgrowth at approximately 50 lM in iPSC-derived neurons which was higher than what was observed in this study and at a level higher than what was observed in the report on humans exposed to CPF (mother and newborns) (Huen et al., 2012) . The differences in cell line sensitivity could be due to several factors. One possible reason is that in the iPSC study, measurements were not restricted to mature MAP2þ neurons as was done in our system, where 98.5% of the cells were mature neurons (Druwe et al., 2015) . Human iPSC-derived neurons cocultured with rat astrocytes were used in neuronal network function assays but human and animal cell cocultures may not accurately represent the human CNS (Harrill et al., 2010; Odawara et al., 2014) . Apart from better representation of an interactive multicellular environment, human astrocytes differ from rodent astrocytes. Human astrocytes are larger, have more complex morphologies than rat astrocytes and a total arborization length significantly greater than that of rat astrocytes in vitro (Oberheim et al., 2009; Zhang et al., 2016) . In addition, fetal human astrocytes are less sensitive in terms of glutamate responses than rat astrocytes from a developmentally comparable stage (Zhang et al., 2016) . Taken together, our human stem cell-based astrocyte-neuron coculture model is a significant advancement in predictive neurotoxicity.
To test our DNT system, we used CPF as a neurotoxicant. CPF is metabolized in human hepatocytes to 2 other forms, CPO and TCP, with differing neurotoxicity. We assessed the effects of each form individually on the neurons. In a dose-response experiment, the highest CPF dose tested (30 mM) was cytotoxic but similar toxicities were not observed for the other 2 forms, suggesting CPF is the most cytotoxic form for this system. Analysis of neurite outgrowth in the same cultures however showed that both CPF and CPO significantly reduced one or more endpoints, such as the number of neurites, neurite length, or branch points per neuron, suggesting both forms were specifically neurotoxic. TCP, on the other hand, did not affect any of these endpoints at doses up to 30 mM. These results are consistent with studies using a zebrafish model where axon outgrowth was significantly inhibited by CPF but not TCP (Yang et al., 2011) .
Comparing CPF toxicity in our human neuron-astrocyte coculture system with neuron-only cultures, we saw a decrease in total cell numbers at 30 mM CPF in both. The extent of this cytotoxic effect was not significantly different in the 2 cultures, suggesting a lack of astrocytic influence on CPF-induced cell death. However, analyses of neurite outgrowth in the same cultures showed a significant effect of astrocytes on multiple endpoints. All 3 endpoints were tested and the number of neurites, neurite length, and branch points per neuron, were significantly reduced in the neuron-only cultures, as expected, at CPF concentrations lower than 30 mM. For all 3 endpoints, astrocytes significantly reduced the negative impact of CPF, suggesting a neuroprotective effect. We also screened additional compounds (amoxicillin, retinoic acid, permethrin, testosterone, diethylstilbestrol, bisphenol A). Unlike CPF exposure, for compounds that affected neurons the astrocytes were not neural protective. No significant difference was observed between neuron-only and neuron-astrocyte cocultures (Supplementary Figure 1) , suggesting that the observed astrocyte protective effect is not a general phenomenon and is compound specific.
CPF is metabolized to CPO and TCP via a P450-dependent mechanism in human hepatocytes and liver microsomes, (Lee et al., 2009) . Human liver cells convert CPF to CPO and then to TCP (Poet et al., 2003) . Since the CPF metabolite TCP did not affect neurite outgrowth or cell density when tested independently on our neurons, possible conversion of CPF to TCP in cocultures could cause the observed astrocyte neuroprotective effect. This hypothesis was further supported by the known presence of P450 enzymes in astrocytes. P450 subtype CYP2B6 is responsible for metabolism of CPF to TCP in liver cells and CYP2B6 is highly expressed in human astrocytes (Miksys et al., 2003) . Consistent with this, we showed here that TCP metabolite concentration significantly increased in astrocytes, both alone and in coculture after a 48 h CPF exposure, when compared with the similarly exposed neuron-only group. This observed difference suggests a role for astrocytic P450-based metabolism of CPF and the observed neurite outgrowth protective results.
To investigate the role of P450 activity in astrocytes using neurite high content imaging, we added the known P450 inhibitor SKF525A to CPF treated cocultures. SKF525A (50 mM) was previously used to inhibit P450 activity (Schuh et al., 2002) ; however, this high concentration was cytotoxic in astrocytes and neurons with neurons affected as low as 20 mM. Based on the observed decrease branch points per neuron in the presence of CPF and SKF525A, we believe the inhibitor decreased P450 mediated astrocytic metabolism of CPF to TCP and thus reversed, in part, some astrocyte protective properties branchpoints at 10 mM SKF525A. A less cytotoxic P450 inhibitor that could be used at a higher and more effective dose may have inhibited neurite number and length. It is possible that not all astrocyte protective mechanisms are mediated through P450. In a rat primary astrocyte and neuron coculture with diazinon and diazoxon, the astrocytes protective effect was attributed to modulation of neuronal GSH content (Pizzurro et al., 2014) . This study used similar doses of diazinon and diazoxon (1 and 10 mM) as we used here for CPF and it is plausible that astrocytes could act via multiple neuroprotective mechanisms (P450 and GSH content). Also, Neurite branching and length are regulated by different molecules (Gallo, 2011) . Doublecortin, Akt, Arp2/3 have a positive role in neurite branching but not in neurite extension (Markus et al., 2002; Strasser et al., 2004; Tint et al., 2009) . CPF decreases transcript levels of doublecortin (Wang et al., 2013) . Together, this implies that CPF may specifically have affected the branching through separate pathways, one being altered by SKF525A, in this astrocyte-neuron coculture system. This study implies that hNP cell-derived astrocytes metabolized neurotoxic CPF to nontoxic TCP, as demonstrated by the P450 inhibition results. In mouse primary astrocyte cultures, the xenobiotic phenytoin was affected by astrocytic P450 active metabolism (Meyer et al., 2001) . However, it is important to note that humans and mice are different in P450 isoform composition, expression and catalytic activities (Nelson et al., 2004) . CYP1A, -2C, -2D, and -3A show appreciable interspecies differences in terms of catalytic activity and some caution should be applied when extrapolating metabolism data from animal models to humans (Martignoni et al., 2006) . This is the first demonstration of a human stem cell-derived astrocyte P450 activity in neuroprotection. Finding an active P450-based mechanism in hNP-derived astrocytes enables further studies using this unlimited human cell source to study xenobiotic toxification and detoxification through P450 in astrocytes in vitro.
Further characterization of P450 subtypes in human stem cell-derived astrocytes is required. It will be important to identify P450 activity and subtypes in hNP cell-derived astrocytes not only for CPF metabolism but also for predicting metabolism of other organophosphorus pesticides. Cultured hepatic cells have reduced P450 activities in comparison with human liver due to P450 transcriptional decreases in vitro. The decreased activities correlate with an alteration in the expression of key transcription factors that govern P450 transcription (RodriguezAntona et al., 2002) . Since astrocytes were derived in vitro from hNP cells, P450 activity could also be lower in these cells compared with astrocyte P450 activity in vivo (Wright and Paine, 1992) .
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